Connect with us

Media & Technology

Current, AcnEase; the Rise of Herborium Group, Inc. (OTCMKTS: HBRM)

Published

on

Herborium Group, Inc. (OTCMKTS: HBRM) is moving up the charts in recent weeks as the Company is becoming current on OTCMarkets with the recent filing of a number of quarters including for the period ending August 31, 2020. The stock is quickly attracting a fast growing shareholder base who continues to heavily accumulate.

HBRM is making money off its acne product AcnEase recently reporting a net income in the past 3 quarters with revenues of $260,000 for the 3 months ended August 31, 2020. The Company has very little debt and no big notes on the books and states on its website its longer-term pipeline includes arthritis candidate and the anti-infectious product candidate focused on antibiotic resistant infections. The Company has a strong team behind it and is led by its founder, high level biotech exec Agnes Olszewski, PhD, founding partner of ClearSign Diagnostics (CSD) and holding 66,7% preferred A shares of HBRM. Other founding partner CSD James Gilligan holds 33,3% pref A of HRBM and is also co founder of Osteon therapeutics.

Herborium Group, Inc. (OTCMKTS: HBRM) is a novel botanical therapeutics® company focused on developing, licensing, and marketing of proprietary, botanical based medicinal products, targeting unmet medical needs. The Company responds to both consumers and healthcare professionals demand for safe, efficacious, all natural medicinal options for treatment and prevention of selected diseases and health concerns. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The potential for this market assesses for over $125 Billon in the USA and UK alone.

This new market is presently positioned for exponential growth since it represents a compelling response to changing needs of a healthcare sector. For the industry, botanical therapeutics provide a value added approach based on product differentiation, higher profit margins, and intellectual property protection with a lower risk and regulatory burden and lower cost. Nutraceuticals (supplements) face increasing FDA and market scrutiny, with massive competitive pressures. To meet the needs of this new growing market opportunity for a diverse spectrum of botanically based drugs, along with complementary and non-traditional therapies, Herborium introduces its own botanical therapeutics® defined as “bridge products”, an emerging category of natural medicines whose safety and efficacy are validated through clinical studies.

Botanical Therapeutics® represents benefits and attributes of both aforementioned traditional sectors. Botanical Therapeutics bring the intellectual property value, posology, clinical validation and rapid market entry while maintaining a safety profile of botanical ingredients and offering the benefits of preventive medicine and cost containment. For its own Botanical Therapeutics the Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its proprietary therapeutic candidates from Traditional Chinese Medicine with initial confirmatory data and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to the Western markets. This strategy serves to mitigate risk in the product development and marketing strategies.

To Find out the inside Scoop on HBRM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

HBRM

The Company secured a pipeline of botanical ingredient based products in the areas of dermatological needs, Prostate Health (BPH), Liver Diseases, Women’s Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. The longer-term pipeline includes arthritis candidate and the anti-infectious product candidate focused on antibiotic resistant infections. Herborium Managements represents a unique blend of expertise with over 50 years of successful business dealings in Asia, an exceptional track record in pharmacology and drug development, clinical testing and regulatory affairs in the US and Europe, supported by high standards, know how in herbal science and formulation, and specifically Modern Chinese Medicine.

Herborium presently sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce. With initial seed investment brought to the Company by Friends and Family and a small professional round, spear-headed by Southridge Investment Group LLC, the Company is ideally positioned for exponential growth in the near future. Down economic times are actually realizing an additional pressure on the sector, and both consumers and insurance companies look for safer and more affordable healthcare options

Since commencing  sales  of  its  principal  product,  AcnEase,  the  Company  has purchased all  of  the  product sold, and held in inventory from AH USA, a USA -based business entity owned by the individual who is the inventor and sole owner of AcnEase,  an acne product.  The Company is party to a licensing agreement with AH USA under which the Company, as licensee, is the exclusive worldwide distributor of AcnEase. The CEO of HBRM is founding partner of ClearSign Diagnostics (CSD) and holding 66,7% preferred A shares of HBRM. Other founding partner CSD James Gilligan holds 33,3% pref A of HRBM and is also co founder of Osteon therapeutics.

https://twitter.com/ToddAnd87820951/status/1343257559050948609

For more on HBRM Subscribe Right Now!

HBRM is moving up the charts in recent weeks as the Company is becoming current on OTCMarkets with the recent filing of a number of quarters including for the period ending August 31, 2020. The stock is quickly attracting a fast growing shareholder base who continues to heavily accumulate. HBRM is making money off its acne product AcnEase recently reporting a net income in the past 3 quarters with revenues of $260,000 for the 3 months ended August 31, 2020. The Company has very little debt and no big notes on the books and states on its website its longer-term pipeline includes arthritis candidate and the anti-infectious product candidate focused on antibiotic resistant infections. The Company has a strong team behind it and is led by its founder, high level biotech exec Agnes Olszewski, PhD, founding partner of ClearSign Diagnostics (CSD) and holding 66,7% preferred A shares of HBRM. Other founding partner CSD James Gilligan holds 33,3% pref A of HRBM and is also co founder of Osteon therapeutics. We will be updating on HBRM when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with HBRM.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in HBRM either long or short and we have not been compensated for this article.

 

 

 

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

LAVA Therapeutics (NASDAQ: LVTX) Gammabody™ Platform Gains Momentum

Published

on

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc. chose a lead candidate.

LAVA Therapeutics N.V. (NASDAQ: LVTX) shares soared 106% as the company announced that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, chose a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.

GAMMABODY™ PLATFORM

LAVA primarily focuses on revolutionizing cancer therapy by developing its Gammabody™ platform. This platform enables them to create bispecific gamma delta T cell engagers that can activate a specific subset of gamma-delta T cells called Vγ9Vδ2 (Vgamma9 Vdelta2) T cells. By utilizing this approach, they aim to enhance the natural recognition of tumors, guide Vγ9Vδ2 T cells to target the tumor cells directly and trigger a cascade of immune responses.

To Discover the Inside Scoop on LVTX, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

What sets their Gammabody™ drug candidates apart is their exceptional performance and safety profiles observed in preclinical studies. Compared to other bispecific T cell engager approaches, their candidates have demonstrated superior efficacy and preferred targeting tumor cells. This targeted approach has the potential to minimize toxicity in healthy tissues.

In May 2020, LAVA entered into a research collaboration and license agreement with Janssen, a subsidiary of the Janssen Pharmaceutical Companies of Johnson & Johnson. This collaboration aimed to discover and develop novel bispecific antibody-based gamma delta T cell engagers for cancer treatment. The agreement was facilitated by Johnson & Johnson Innovation, emphasizing their commitment to fostering innovation in the field.

As part of the collaboration, LAVA had the opportunity to receive potential milestone payments and royalties based on the successful development, regulatory approvals, and commercialization of the candidates. This incentivized LAVA to actively pursue the discovery and advancement of promising lead candidates. 

The collaboration represents a remarkable milestone many early-stage biotech companies aspire to achieve. Partnering with a program brings numerous benefits, including reduced risk of dilution through milestone payments as the trials advance and streamlined commercialization once the product receives approval.

Under the terms of the agreement, Janssen will assume responsibility for the selected candidate’s future clinical development, manufacturing, and commercialization. This includes bearing the costs and expenses associated with these activities.

Stephen Hurly, LAVA Therapeutics’s president and chief executive officer, expressed satisfaction with Janssen’s selection of a lead candidate for clinical studies. He emphasized LAVA’s pioneering role in developing gamma-delta bispecific antibodies through their proprietary Gammabody platform. This platform and LAVA’s extensive expertise in bispecific antibody development position them at the forefront of advancing novel therapies for cancer patients.

In summary, LAVA Therapeutics’ collaboration with Janssen has reached a significant milestone in selecting a lead candidate for further development toward clinical studies. This progress underscores LAVA’s dedication to leveraging its Gammabody platform and expertise in bispecific antibody development to revolutionize cancer treatment.

We will update you on LVTX when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Continue Reading

Featured

Onfolio Holdings (NASDAQ: ONFO) Unleashing the Power of AI

Published

on

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com.

Onfolio Holdings Inc (NASDAQ: ONFO), a technology services company, has recently introduced an advanced generative AI search function for its subsidiary, MightyDeals.com. The implementation of this innovative AI tool, powered by chatGPT-style Large Language Models (LLMs), has resulted in a surge of 105% in the company’s stock price and sparked tons of investor interest. The company has a 3.28M float and, at the time of writing, has traded 20x that amount, with a colossal 60M shares exchanging hands.

Revolutionizing User Experience and Driving Stock Surge

With the integration of AI search on MightyDeals.com, customers can now use natural language to describe the products they seek, simplifying the buying process. The AI tool utilizes contextual understanding and description analysis of hundreds of active deals to generate instant search results based on users’ queries. By enhancing the user experience, Onfolio Holdings anticipates increased user return rates, higher site interaction rates, and elevated revenues for MightyDeals.com. This groundbreaking development has attracted positive attention, significantly increasing Onfolio Holdings’ stock price.

To Discover the Inside Scoop on ONFO, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Evaluating Financial Performance

While the stock surge indicates investor enthusiasm, assessing Onfolio Holdings’ financial performance is crucial for comprehensive investment analysis. The positive earnings growth of +44.44% and revenue growth of +22.74% contribute to the company’s optimistic outlook. However, investors should be cautious of the negative net profit margin of -190.75% and the lack of available price/book ratio data. Monitoring the company’s financial performance leading up to the next reporting date on August 30, 2023, is advised to understand its profitability and overall stability better.

Investment Outlook and Future Prospects

Considering the stock surge and optimistic price forecasts, Onfolio Holdings has promising prospects. Analysts offer a median target price of $3.00 for the company’s stock, signaling an expectation of significant growth within the next 12 months. However, it is essential to note that Onfolio Holdings operates at a loss. Investors should thoroughly evaluate the company’s long-term growth potential and weigh the potential returns against the inherent risks before making investment decisions.

About MightyDeals.com

Mighty Deals is a free daily deals website aimed at creative professionals focusing on products and services for web designers and developers. The site offers fantastic deals on quality fonts, templates, apps, add-ons, plug-ins, ebooks, icons, and more. The site provides discounts on packages which usually range between 50%-97% off but are only available for a limited time. MightyDeals.com boasts an exceptional return rate from its users and is one of Onfolio Holdings’ highest revenue-generating subsidiaries.

About Onfolio Holdings Inc.

Onfolio acquires and manages a diversified portfolio of online businesses across a broad range of verticals, each with a niche content focus and brand identity. Onfolio acquires firms that meet its investment criteria, being that such businesses operate in sectors with long-term growth opportunities, have positive and stable cash flows, face minimal threats of technological or competitive obsolescence, and can be managed by our existing team or have strong management teams largely in place. The Company excels at finding acquisition opportunities where the seller has not fully optimized their business. Onfolio’s experience and skillset allow it to add increased value to these existing businesses.

Conclusion

Onfolio Holdings’ introduction of the generative AI search function for MightyDeals.com has increased the company’s stock price, reflecting the market’s positive response to this innovative technology. The enhanced user experience and the potential for increased revenues have positioned Onfolio Holdings as a leader in the tech industry. However, investors must carefully consider the company’s financial performance and evaluate its long-term growth potential before making investment decisions. Monitoring the company’s performance to the next reporting date will provide valuable insights into its financial health and stability.

We will update you on ONFO when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by James from Pixabay

Continue Reading

Featured

Enveric Biosciences (NASDAQ: ENVB) Pioneering the Future of Anxiety Disorder Treatment

Published

on

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news.

Enveric Biosciences, Inc. (NASDAQ: ENVB) shares surged 78% this morning upon approval of some fantastic news. The United States Patent and Trademark Office has granted them a notice of allowance for their patent application concerning a groundbreaking chemical compound called EB-373. This compound is being developed to address the treatment of anxiety disorders.

The forthcoming patent, titled “C4-Carbonothioate-Substituted Tryptamine Derivatives and Methods of Using,” encompasses claims for the composition of matter of a family of revolutionary prodrug derivatives of psilocin. Enveric’s lead product candidate, EB-373, stands out among these derivatives. A Notice of Allowance signifies that the USPTO has determined that a patent should be granted based on the submitted application.

To Discover the Inside Scoop on ENVB, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Enveric’s commitment to innovation extends beyond EB-373. They have also submitted additional patent applications to the USPTO, exploring psilocin prodrugs with unique crystalline molecular structures. Moreover, they have taken proactive steps to pursue global coverage of the EVM201 and EVM301 Series through companion Patent Cooperation Treaty and non-US national patent applications. Encouragingly, positive International Search Reports and written opinions have been received under the Patent Cooperation Treaty for most of these applications.

Joseph Tucker, Ph.D., Enveric’s director and CEO, underlined the significance of the USPTO’s favorable decision concerning their lead candidate, EB-373. He highlighted the innovative designs of their psilocin prodrugs within the EVM201 series, differentiating them from conventional counterparts like psilocybin. These novel designs hold the potential to deliver more rapid therapeutic effects, precise control, and reduced gastrointestinal side effects. Tucker emphasized that securing a robust intellectual property portfolio for their new chemical entity prodrugs is pivotal to Enveric’s value proposition and integral to their business strategy of developing cutting-edge small-molecule therapeutics to address mental health disorders.

We will update you on ENVB when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gino Crescoli from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.